Drug Trial Radar · NCT04165993
Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
68
Actual
Start
Dec 31, 2019
Primary completion
May 27, 2021
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, three-cohort phase 2 study of KN026 in subjects with advanced breast Cancer.
Conditions
- Metastatic Breast Cancer
Interventions
Concurrent chemotherapy and KN026Drug
30 mg/kg Q3W KN026 75 mg/m2 docetaxol
KN026 monotherapyDrug
30 mg/kg Q3W KN026
KN026 combinationDrug
30 mg/kg Q3W KN026 5 mg/kg Q3W KN046
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Throughout the duration of the study; up to 2 years
- Duration of response (DOR)Time frame: up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.